Development of anidulafungin for disk diffusion susceptibility testing against Candida spp.

被引:6
作者
Jones, Ronald N. [1 ]
Kirby, Jeffrey T.
Messer, Shawn A.
Sheehan, Daniel J.
机构
[1] JMI Labs, N Liberty, IA 52317 USA
[2] Tufts Univ, Sch Med, Boston, MA 02111 USA
[3] Pfizer, New York, NY 10017 USA
关键词
disk diffusion; echinocandin; anidulafungin; yeast; M44-A; error rates;
D O I
10.1016/j.diagmicrobio.2007.01.018
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
A disk diffusion (DD) method has been standardized by the Clinical and Laboratory Standards Institute (M44-A) to test Candida susceptibilities for some azoles (fluconazole and voriconazole). The DD method using anidulafungin, a new echinocandin, was initially developed here using Candida spp. (75 strains) and candidate anidulafungin disk concentrations of 1, 2, 5, and 10 mu g with or without dimethyl sulfoxide (DMSO) (0.05-1%) and with or without polysorbate 80 (P-80, 0.002-2%). The 2-mu g disks (with 1 % DMSO and 0.1 % P-80) produced acceptable correlation statistics (r = 0.84-0.85) when compared with reference MIC results, and this disk was optimal for testing all Candida spp. Good separation of Candida parapsilosis (least anidulafungin-susceptible species) from the more susceptible yeast species and a potential susceptibility breakpoint near the preferred reproducible zone diameter of >= 15 mm were achieved for all tested yeast species. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:371 / 374
页数:4
相关论文
共 18 条
[1]   Precision and accuracy of fluconazole susceptibility testing by broth microdilution, Etest, and disk diffusion methods [J].
Barry, AL ;
Pfaller, MA ;
Rennie, RP ;
Fuchs, PC ;
Brown, SD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) :1781-1784
[2]   Nosocomial bloodstream infections in United States hospitals: A three-year analysis [J].
Edmond, MB ;
Wallace, SE ;
McClish, DK ;
Pfaller, MA ;
Jones, RN ;
Wenzel, RP .
CLINICAL INFECTIOUS DISEASES, 1999, 29 (02) :239-244
[3]   Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion [J].
Hazen, KC ;
Baron, EJ ;
Colombo, AL ;
Girmenia, C ;
Sanchez-Sousa, A ;
del Palacio, A ;
de Bedout, C ;
Gibbs, DL .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (12) :5623-5632
[4]   Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole [J].
Matar, MJ ;
Ostrosky-Zeichner, L ;
Paetznick, VL ;
Rodriguez, JR ;
Chen, E ;
Rex, JH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (05) :1647-1651
[5]   Initial results from a longitudinal international surveillance programme for anidulafungin (2003) [J].
Messer, SA ;
Kirby, JT ;
Sader, HS ;
Fritsche, TR ;
Jones, RN .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (06) :1051-1056
[6]   International surveillance of Candida spp. and Aspergillus spp.:: Report from the SENTRY Antimicrobial Surveillance Program (2003) [J].
Messer, Shawn A. ;
Jones, Ronald N. ;
Fritsche, Thomas R. .
JOURNAL OF CLINICAL MICROBIOLOGY, 2006, 44 (05) :1782-1787
[7]   Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained:: a potential risk factor for hospital mortality [J].
Morrell, M ;
Fraser, VJ ;
Kollef, MH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (09) :3640-3645
[8]  
*NAT COMM CLIN LAB, 2001, M23A2 NAT COMM CLIN
[9]  
National Committee for Clinical Laboratory Standards, 2004, M44A NAT COMM CLIN L
[10]  
National Committee for Clinical Laboratory Standards, 2002, M27A2 NAT COMM CLIN